Loading...

SCLX SCILEX HOLDING CO US FDA Inspections 8-K Filing

SCLX

SCLX

SCILEX HOLDING CO

(SCLX)

2023 8-K

Show Summary

Show Summary

Deferment of Dividend

Investor Meetings

Compensatory Arrangements o...

Changes in capital structure

Dividend Date Change

Stock Split Approval

Dividend Date Change

Sales Agreement Termination

Royalty Agreements

License Agreement

Nasdaq Compliance

Debt Restructuring

Dividend Record Change

Joint Venture Announcement

Debt Restructuring

Accountant Change

Director Resignation

Nasdaq Compliance Issues

Auditor Dismissal

Accountant Change

Business Combination

Preferred Stock Issuance

Q3 2024 Results

Debt Refinancing

Payment Agreement

Securities Agreement

Merger Agreement

Financial Results

Appointment of Director

Settlement Agreement with V...

Business Combination Announ...

Financial Results

Dividend Authorization

Investment and Payment

Exploring Value Maximization

Entry into a Material Defin...

Regulation FD Disclosure

Press Release on Market Man...

Disclosure of Short Selling

Securities Purchase Agreement

Financial Results

Annual Meeting of Stockholders

Lock-up Period Extension

Termination of Agreement

Settlement Agreement and Li...

Underwriting Agreement

Settlement Agreement with V...

Termination of Agreement

Lawsuit and Settlement Agre...

Financial Results

Sales Agreement

Financial Results

Financial Results

Amendment to Convertible De...

Departure of Directors or C...

Debt Issuance and Terminati...

Resignation, Appointment, T...

Settlement Agreement with I...

Bankruptcy or insolvency

Financial Results

Resignations and Retirement

Earnings Guidance

Credit Agreement

Regulation FD Disclosure

Financial Results

Annual Meeting of Stockholders

Financial Results

Lock-up Period Extension

Entry into Material Definit...

Entry into Material Definit...

Financial Results

Securities Purchase Agreement

Financial Results

Acquisition of Rights to EL...

Equity Purchase Agreement

Annual Meeting Announcement

Disclosure of Stock Dividend

Financial Results

FAQ Disclosure and Press Re...

Management Change

Equity Purchase Agreement

Financial Results

External Links:

Scilex Holding Co announces agreement with FDA for clinical development of SP-102 in Lumbosacral Radicular Pain and requirements for New Drug Application.

AI Assistant

SCILEX HOLDING CO

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.